ADVANZ PHARMA — Investor Presentation (June 2019)
33 slides from ADVANZ PHARMA's investor presentation, June 2019
Slide 1: ADVANZ PHARMA Corporate Presentation – June 2019
ADVANZ PHARMA The leading global platform for niche- established medicines Corporate Presentation – June 2019
Slide 2: Important Notices
Important Notices Notice Regarding Forward-Looking Information Some statements and information contained in this presentation are forward‐looking statements or forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Investor
Slide 3: Today's Presenters
Today’s Presenters CEO CFO Graeme Duncan Adeel Ahmad • Appointed as CEO in July 2018 • Appointed as CFO in July 2018 • Joined in October 2014 as UK General • Joined in October 2013 as Vice President Manager and Global Marketing Director of Finance and Controller of Concordia AMCo International Corp.
Slide 4: Agenda
Agenda 1) Introduction to ADVANZ PHARMA 2) Company Highlights 3) Industry Positioning 4) Historical Financials and Current Trading 4
Slide 5: Introduction to ADVANZ PHARMA
Introduction to ADVANZ PHARMA
Slide 6: ADVANZ PHARMA at a Glance
ADVANZ PHARMA at a Glance Overview 2018 Revenue Breakdown • A leading global platform for niche-established medicines By Geography By Therapeutic By Molecule area • Highly diverse product portfolio 127 10.7% Molecules • 190+ legacy brands and niche generic medications 14 Neurology 15% Macrobid/ Macr
Slide 7: 2018 Recapitalization – A Transformatory Transaction…
2018 Recapitalization – A Transformatory Transaction… Transaction Overview New Shareholding Structure(1) Peers Leverage Stats(2) 7.1x • In September 2018, ADVANZ PHARMA successfully completed the recapitalization of its balance sheet 6.0x 5.7x c.5x(3) 4.5x • The transaction resulted in a significant
Slide 8: …Repositions Us for Potential Long-Term Growth
…Repositions Us for Potential Long-Term Growth Pre-Recapitalization Today 1 In October 2015, acquired AMCo for US$3.5bn (13.7x LTM EV / Leverage Adj. EBITDA), weaker equity market conditions impacted Current leverage(1) of 4.5x net debt / LTM adj. EBITDA ability to raise equity resulting in net leve
Slide 9: Low Risk Business Model Focused on Well-established, Off-patent Originator Brands
Low Risk Business Model Focused on Well- established, Off-patent Originator Brands On-Patent Off-Patent Pharmaceutical Product Life Cycle Total Generics enter market Revenue Patent Competition Volume increase through expiry ADVANZ PHARMA FOCUS AREA sales and marketing Price decrease Stable prici
Slide 10: Implementing P.L.A.N. – Growth and Operational Initiatives
Implementing P.L.A.N. – Growth and Operational Initiatives Product Expansion Leverage Global • We intend to expand our product Capability portfolio to deliver mid-term value and • People, commercial, geography. long-term growth, through pipeline, We will deliver a lean and fully STRATEGIC GUIDING PO
Slide 11: Four Growth Pillars Underpin Strategy
Four Growth Pillars Underpin Strategy 1 2 Disciplined and Focused M&A Strategy Licensing Opportunities • Refocus on M&A opportunities • Licensing and distribution deals in single or multiple territories • Disciplined approach with well-defined criteria and review process • Leverage existing market p
Slide 12: Case Study: Recent Product Acquisition
Case Study: Recent Product Acquisition Transaction Background Products Overview • On March 31, 2019, ADVANZ PHARMA acquired the international rights to Salagen® tablets (pilocarpine Salagen® hydrochloride) (excluding Japan rights) and Panretin® • Indications include treatment of (alitretinoin) gel 0
Slide 13: Case Study: Proven Development Capabilities for Complex Niche Generics
Case Study: Proven Development Capabilities for Complex Niche Generics Key Highlights Total Market Opportunity excl. U.S. (US$m)(1) CAGR • ADVANZ PHARMA has recently developed a differentiated 15-18 version of a Somatostatin Analogue (long-acting injectable) $1,361 +5% $1,262 $1,301 for acromegaly a
Slide 14: Company Highlights
Company Highlights ADVA\NZ PHARMA
Slide 15: Key Company Highlights
Key Company Highlights Highly diversified Attractive portfolio of off-patent mature brands and niche / specialty generics 1 portfolio of niche- established Decades of prescription history and safety profile resulting in strong patient and prescriber loyalty Highly diversified portfolio of 190+ molec
Slide 16: Highly Diversified Portfolio of Niche-Established Medications
1 Highly Diversified Portfolio of Niche-Established Medications Year of Competitive 2018 Revenue Top 15 Molecules / Brands Indications No. of SKUs No. of countries Launch Position Contribution (%) Macrobid / Macrodantin 1953 Urinary tract infections 21 11 – 20 10.7% Zonegran 1989 Epilepsy 2 1–5 7.1%
Slide 17: Global Product Portfolio Marketed Across 90+ Countries
2 Global Product Portfolio Marketed Across 90+ Countries UK RoW North America • 127 molecules sold to pharmacies • 109 molecules sold in 91 markets • Highly cash-generative business and hospitals • Highly diversified business with relying on 14 brands and 6 predictable cash flow generation authorize
Slide 18: Our Global Footprint Positions Us as Partner of Choice for Product Opportunities
2 Our Global Footprint Positions Us as Partner of Choice for Product Opportunities • Global network of partners in over 90+ countries • Commercial footprint through direct presence in 7 countries • Area managers in 8 countries and distributor relationships in other markets 2018 Revenue by Geography
Slide 19: Asset-Light Business Model Focused on Critical Parts of the Value Chain
3 Asset-Light Business Model Focused on Critical Parts of the Value Chain Managed Low risk Internal Fully- Outsourced to Key Points by In- development capabilities in outsourced to third-party box • Core focus on key licensing outsourced to UK and Ireland third-party distributors / sales CMO third-p
Slide 20: Manufacturing Outsourced and Managed Through a Strong Network of High Quality CMOs
3 Manufacturing Outsourced and Managed Through a Strong Network of High Quality CMOs Key Points Wide Network of High Quality Sites • 70 active CMOs • Focus on European CMOs for RoW markets • North American sites for NA market • 7 of the top 10 EU CMOs work with ADVANZ PHARMA • Partnership approach w
Slide 21: Unique India Centre of Excellence Providing Key Competitive Advantage
3 Unique India Centre of Excellence Providing Key Competitive Advantage Key Points Employee Corporate Supply chain Support and Commercial Scientific affairs Total (Mar-19) locations development management management • India Centre of Excellence combines essential back office support with front end 2
Slide 22: Highly Experienced Executive Management Team
4 Highly Experienced Executive Management Team New management team with significant industry experience Graeme Duncan Chief Executive Officer 20+ years of experience Adeel Ahmad Rob Sully Karl Belk Guy Clark Paul Burden Simon Tucker Glenn Kutschera Chief Operations Chief Corporate President of UK &
Slide 23: Industry-leading Profitability and Cash Flow Profile
5 Industry-leading Profitability and Cash Flow Profile FY18 EBITDA Margin (%) 57% 47% (1) 39% 37% 31% 30% 26% 24% 23% Advanz Chep Karo Recordati Riemser Orion Alliance Dermapharm Stada FY18 Cash Conversion (%)(2) 98% (1) 97% 91% 83% 83% 82% 77% na na Advanz Karo Alliance Recordati Stada Dermapharm O
Slide 24: Industry Positioning
Industry Positioning ADVA\NZ PHARMA
Slide 25: We Believe we are Well-Positioned to Benefit from the M&A Momentum in the Mature Brands Sector…
We Believe we are Well-Positioned to Benefit from the M&A Momentum in the Mature Brands Sector… Strong pipeline of attractive product M&A as big pharma look to divest off-patent originator brands to focus on top-line growth and their core innovation business “We continue to streamline our portfolio,
Slide 26: …as we have Significantly Revitalized our M&A Capabilities
…as we have Significantly Revitalized our M&A Capabilities 5 Strong M&A war 4 chest Access to key 3 decision makers • Balance sheet cash Highly disciplined and well- available to deploy 2 defined review process • Years of experience Integration and expertise in the • Strong cash flow 1 Capabilities
Slide 27: We are a Partner of Choice for M&A and Licensing Opportunities
We are a Partner of Choice for M&A and Licensing Opportunities Key focus areas when choosing Meeting the criteria of a strong M&A or in-licensing partner the right partner 1 Geographic reach, commercial ✓ The largest pure-play provider of established branded off-patent medications capabilities and d
Slide 28: We are The Leading Global Platform for Niche-Established Medicines
We are The Leading Global Platform for Niche- Established Medicines Company Scale (Revenue) Global Reach Shareholder base Investment in pipeline Majority owned by three anchor US$520m investors – GSO (part of the Blackstone ✔ Group), Bybrook and Solus €292m Family owned £124m Diversified institution
Slide 29: Historical Financials and Current Trading
Historical Financials and Current Trading
Slide 30: Revenue Bridge By Product
Revenue Bridge By Product 11. Donnatal − Pressure from two competitive products on Donnatal® tablets and the launch of two non-FDA approved competitive products to Donnatal® Elixir resulted in lower product volumes and revenue during the period. The product now contributes 4.5% to the LTM Q1’19 Grou
Slide 31: Highly Cash Generative Financial Profile
Highly Cash Generative Financial Profile US$m 2017A 2018A LTM Q1’19A Key Points Total Revenue(1) 626.2 537.0 520.4 • Highly cash generative business % Growth (14.2%) (3.1%) o/w UK & RoW 465.4 403.7 389.8 with strong cash conversion %Growth (13.3%) (3.4%) o/w North America 160.8 133.3 130.6 • Operati
Slide 32: Current Trading – Q1 2019
Current Trading – Q1 2019 Revenue (US$m) Gross Profit (US$m) and Margin (%) Key Points 190 80% 66% 68% 68% 66% 67% • Relatively consistent financial 152 70% 139 136 128 140 60% performance over the last four 39 118 33 37 101 50% 36 25 95 91 quarters 87 78 90 40% 30 27 29 29 21 30% • Gross profit and
Slide 33: Near-term Management Focus
Near-term Management Focus • Recent acquisition of Salagen® and Panretin® validates strategic re-focus and ability to execute on value accretive M&A. Management is highly focused on integrating the two products Acquisition Opportunities • Continue to review additional product and platform acquisitio